Marijuana and Prescription Pain Reliever Use among Cigarette Smokers. by Goldberg, Rachel L & Cataldo, Janine K
UCSF
UC San Francisco Previously Published Works
Title
Marijuana and Prescription Pain Reliever Use among Cigarette Smokers.
Permalink
https://escholarship.org/uc/item/97z6x202
Journal
Journal of psychoactive drugs, 50(4)
ISSN
0279-1072
Authors
Goldberg, Rachel L
Cataldo, Janine K
Publication Date
2018-09-01
DOI
10.1080/02791072.2018.1506598
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Marijuana and Prescription Pain Reliever Use Among Cigarette 
Smokers
Rachel L. Goldberg, BAa,b,c [Clinical Research Coordinator] and Janine K. Cataldo, RN PhD, 
FAANa,b,c [Professor Chair]
aDepartment of Physiological Nursing, University of California, San Francisco, 2 Koret Way, N631, 
San Francisco, CA 94143, USA
bCenter for Tobacco Control Research and Education, Cardiovascular Research Institute, 
University of California, San Francisco, 530 Parnassus Ave, San Francisco, CA 94143, USA
cTobacco Center of Regulatory Science, University of California, San Francisco, 530 Parnassus 
Ave, San Francisco, CA 94143, USA
Abstract
Due to marijuana’s analgesic effects and its growing national legal status, it is likely that 
marijuana’s rising prevalence will impact prescription pain reliever (PPR) use. The present study 
investigates the relationship between marijuana and PPR use among U.S. adult current cigarette 
smokers. Data were analyzed from the Tobacco and Attitudes Beliefs Survey II, with 348 current 
cigarette smokers, aged 24–88. Logistic regression was used to examine the likelihood of current 
(past 30 days) PPR use by marijuana use (never, ever, and current) among cigarette smokers. 
Among PPR users (N=76), we also investigated whether marijuana use frequency predicted 
current PPR use. Compared to never marijuana users, participants were more likely to report past 
30-day PPR use if they have ever used marijuana (AOR: 2.58, 95% CI: 1.51–4.43) or have used 
marijuana in the past 30 days (AOR: 3.38, CI: 1.76–6.49). No significant relationship was found 
between marijuana use frequency and PPR use. Thus, in this sample of adult cigarette smokers, 
past and current marijuana users were two to three times more likely to report PPR use than never 
marijuana users. These findings can help inform policy makers and healthcare providers in their 
fight against the opioid epidemic.
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INTRODUCTION
In the U.S., use of prescription pain relievers (PPRs), also known as prescription opioids and 
opioid pain relievers, has been increasing dramatically. Worldwide, prescriptions of PPRs 
have almost tripled since 1990, and the U.S. is a factor in this rise, as it has the highest per 
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capita consumption of PPRs in the past ten years (International Narcotics Control Board 
2016). This increase has become dangerous, as opioid use carries risks that include 
addiction, sedation, respiratory depression, overdose (OD) and death (Rudd et al. 2016; 
Benyamin et al. 2008). Between 1999 and 2010, deaths attributed to PPRs rose five times 
among women and 3.5 times among men (Mack, Jones & Paulozzi 2013). Of all prescription 
drug OD deaths in the U.S. in 2013, 71.3% involved PPRs (Mack, Jones & Paulozzi 2013).
PPRs and marijuana (i.e., cannabis) are biologically linked; like PPRs, marijuana induces 
analgesia, acts on some of the same brain regions, and partly exerts its effects via opioid 
receptors (Mack, Jones & Paulozzi 2013; Maione et al. 2011; Lynch & Campbell 2011; 
Cichewicz 2004). This connection is especially relevant due to the changing legal status of 
marijuana. As of August 2016, 24 states and Washington D.C. had legalized medical 
marijuana. Between 2007 and 2012, the number of past month marijuana users rose from 5.8 
to 7.3% (Substance Abuse and Mental Health Services Administration (SAMHSA) 2013), 
and between 2001 and 2013, past year adult marijuana use increased from 4.1 to 9.5% in the 
U.S. (National Institute on Alcohol Abuse and Alcoholism 2015). Further, legalization of 
medical marijuana has been associated with increased odds of marijuana use among adults 
(Wang & Cataldo 2016; Martins et al. 2016; Wang et al. 2016; Cerdá et al. 2012), though no 
consistent association has been determined among youth/young adults (Martins et al. 2016; 
Wall et al. 2016).
Distinct theories attempt to explain how medical marijuana legalization affects use of 
substances other than marijuana. The relationship between different substances can be 
impacted by 1) change in cost of a substance, 2) policy alterations that influence availability 
of a substance, 3) shifts in legal consequences of using a substance, and/or 4) the 
psychoactive/pharmacological effects of a substance (Lucas et al. 2013). More U.S. states 
are legalizing medical marijuana (related to both policy and legal shifts), and marijuana 
shares some psychoactive/pharmacological effects with PPRs.
The substitution theory postulates that there is a substitution effect, whereby an increase in 
marijuana use coincides with a decrease in the use of other substances – in this case, PPRs 
(Lucas et al. 2013; Hursh et al. 2005). There are logical reasons why individuals would opt 
to use marijuana instead of PPRs. With the new legal status of medical marijuana, 
individuals can access it through medical dispensaries and enjoy a lower legal risk if they 
live in a state where it is legalized. Individuals also report switching to marijuana for pain 
control because when compared to prescription drugs, marijuana has fewer side effects and 
withdrawal symptoms (Lucas et al. 2013). Studies supporting the substitution effect have 
demonstrated that either increases in the use of marijuana or the legalization of medical 
marijuana is associated with reductions in opioid use, hospitalizations for opioid 
dependence/abuse, PPR ODs, and opioid OD mortality (Shi 2017; Boehnke, Litinas & 
Clauw 2016; Bachhuber et al. 2014).
In contrast to the substitution effect, there may be a complementary effect, where an increase 
in marijuana use is associated with an increase in the use of PPRs (Lucas et al. 2013; Hursh 
et al. 2005). In support of this theory, researchers using National Survey on Drug Use and 
Health (NSDUH) data found a positive association between marijuana and increased use of 
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PPRs (Novak, Peiper & Zarkin 2016). In another study, researchers focused on individuals 
who were prescribed long-term opioid therapy and found that those who also used medical 
marijuana presented with greater risk of misusing prescription opioids. (Nugent et al. 2018) 
Additionally, a prospective cohort study using the National Epidemiologic Survey of 
Alcohol and Related Conditions (NESARC) data determined that use of marijuana was 
associated with a greater risk of using nonmedical prescription opioids three years later 
(Olfson et al. 2018). However, in these studies, researchers did not analyze how co-use of 
other substances would impact the direction and/or strength of the relationship between 
marijuana and opioids/PPRs. To determine if there is either a substitution or a 
complementary effect between marijuana use and PPR use, co-use with other substances 
needs to be studied.
Additionally, there is a strong positive association between nicotine use and PPR use. When 
compared to non-smokers, tobacco smokers experience more intense and longer lasting 
chronic pain, as well as a higher frequency of PPR use (Yoon, Lane & Weaver 2015; Zale et 
al. 2015; Skurtveit et al. 2010). Studies have demonstrated an interaction between nicotine 
and opioids that is associated with an increase in the total consumption of the two substances 
and contributes to other effects of the drugs (Kohut 2017). The relationship between the use 
of these two substances has a basis in the biological connection between them, as the 
endogenous opioid system is an underlying mechanism for several behavioral outcomes 
related to nicotine (i.e., nicotine craving, anxiolytic and anxiogenic effects, and nicotine 
withdrawal symptoms) (Nuechterlein et al. 2016; Hadjiconstantinou & Neff 2011; 
Berrendero et al. 2010). Like marijuana, nicotine is involved in anti-nociception via 
endogenous opioid system mediation, suggesting that nicotine is used for the self-
medication of pain (Kishioka et al. 2014; Ditre et al. 2016); and in fact, nicotine heightens 
the anti-nociceptive effects of both opioids and marijuana (Kohut 2017). Several studies 
have documented common use patterns among tobacco, marijuana, and opioids/PPRs 
(Arterberry et al. 2016; Abrahamsson & Hakansson 2015; Fiellin et al. 2013). For example, 
a prospective study of NESARC data demonstrated that early-onset of smoking cigarettes 
increased the odds of beginning opioid use and that frequency of both cigarette and 
marijuana use increased the odds of beginning opioid use, re-initiating opioid use after 
previously stopping, and continuing opioid use among current users (Arterberry et al. 2016). 
Thus, the three substances share anti-nociceptive actions mediated by the endogenous opioid 
system, and evidence indicates that marijuana and nicotine use predict opioid use among 
adults.
From 2003 to 2012, NSDUH data revealed a significant increase in the co-use of marijuana 
and tobacco (from 4.4% to 5.2% of the sample) (Schauer et al. 2015). Further, smoking 
tobacco is significantly associated with cannabis dependence (Agrawal and Lynskey 2009). 
Given the national trend toward marijuana legalization, co-use is likely to increase. Cigarette 
smokers and marijuana users are a crucial population to study, as nicotine and marijuana 
share mechanisms of action with each other and with opioids, and use of each substance has 
been shown to be associated with use of opioids/PPRs (Arterberry et al. 2016, Abrahamsson 
and Hakansson 2015, Fiellin et al. 2013, Olfson et al. 2018, Nugent et al. 2018). However, 
whether there is an association between prevalence of marijuana and PPR use among current 
smokers has not been determined. The present study addresses this gap by using the Tobacco 
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Attitudes and Beliefs Survey (TABS) II to investigate the relationship between marijuana 
use and PPR use among current cigarette smokers. This study examines (in cigarette 
smokers) 1) the likelihood of PPR use by marijuana use and 2) the frequency of marijuana 
use and current PPR use. Findings may help elucidate whether marijuana use is associated 
with PPR use, and if so, whether marijuana is used as a substitute or complement to PPR 
use.
METHODS
Data and study sample
This is a cross sectional analysis of data from the TABS II, a web-based longitudinal survey 
of U.S. adult former and current cigarette smokers, aged 24 years old and older. The survey 
included topics such as individuals’ use of tobacco, tobacco-related products, marijuana, and 
other substances including PPRs. The present analysis used demographic data from Wave 1 
(baseline) from August 2015 (see Table 1). Wave 3 data were collected in August 2016 and 
included survey items on marijuana use and new items on PPR use (not included in Waves 1 
or 2).
Surveys were administered by Qualtrics, which uses a combination of online panels to 
establish national samples from which survey participants can be randomly selected. 
Qualtrics invited potential participants to take the survey via an email notification and 
offered them a $10 incentive to complete each survey wave. For Wave 1, 2,378 individuals 
clicked on the survey link, and 819 went on to complete the survey, yielding a completion 
rate of 34.4% (a rate typically seen for Qualtrics online surveys). Current smokers (n = 348) 
were included in the current analysis. The TABS II project was approved by the UCSF 
Institutional Review Board.
Measures
Cigarette use.—Participants were categorized as a current cigarette smoker if they 
responded “yes” to the question, “Are you a current cigarette smoker?” and if they 
responded with any number of days greater than 0 for the question “During the last 7 days, 
on about how many days did you smoke cigarettes, even 1 or 2 puffs” or to the question 
“During the last 7 days, on about how many days did you smoke menthol cigarettes, even 1 
or two puffs.” The question “On average, how many cigarettes a day do you smoke?” was 
used to control for cigarette consumption in the analysis of the relationship between 
cannabis use and PPR use.
Marijuana use.—Definitions of each user type were: “never users,” never used marijuana 
in their lifetime; “ever” users, used marijuana at least once in their lifetime, but not in the 
past 30 days; and “current” users, used marijuana in the past 30 days. If participants 
answered the question “During the last 30 days, on about how many days did you use 
marijuana, even 1 or 2 puffs?” with any number above 0, they were classified as a current 
user. If participants responded with “I have never tried marijuana” to the question asking 
“Which of the following forms of marijuana have you EVER used?” then they were 
classified as a never user. If they responded to this question with any other option besides 
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“Don’t know/refused” and if they were not categorized as a current user, they were classified 
as an ever user. For the analysis involving frequency of marijuana use as a continuous 
variable, responses to the question “During the last 30 days, on about how many days did 
you use marijuana, even 1 or 2 puffs?” were used.
Medical marijuana law (MML) status in state of residence.—Participants were 
categorized as: 1) no legal medical marijuana in state of residence, 2) legal medical 
marijuana for less than 10 years in state of residence, or 3) legal medical marijuana for 10 or 
more years in state of residence.
PPR use.—PPR users were categorized as “never” users if they reported they had never 
used PPRs in their lifetime, as “ever” users if they had used PPRs but not in the past 30 days, 
and “current” users if they had used PPRs in the past 30 days. If participants selected 
“Prescription pain relievers” for the following two questions, they were classified as current 
PPR users: 1) “Have you EVER used any of the following substances? Mark all that apply” 
and 2) “Have you used any of the following substances in the PAST 30 DAYS? Mark all that 
apply.” If participants selected “Prescription pain relievers” in the first question (ever use), 
but did not select them in the second question (past 30 day use), then they were classified as 
ever users. If they did not select “Prescription pain relievers” in the question inquiring about 
ever use, they were classified as never users.
Statistical Analysis—Descriptive analyses were used to test for normality. Chi-square 
tests were used for categorical variables (gender, race/ethnicity, education, occupational 
status, type of community, MLL status in state of residence, and PPR status), and an 
ANOVA was used for the continuous variables (age and average cigarettes smoked per day) 
to compare sample characteristics between marijuana never users, ever users, and current 
users. For PPR status, a Bonferroni adjustment was made to account for multiple 
comparisons.
Logistic regression (both unadjusted and adjusted for the sample characteristics of age, 
gender, race/ethnicity, education, occupational status, type of community, MML status in 
state of residence, and average cigarettes smoked per day) was used to investigate the 
likelihood of PPR use in the past 30 days (reference group = current users) according to 
marijuana use (never, ever, and current). A logistic regression was used to examine whether 
the frequency of marijuana use influenced PPR use among current marijuana users. SAS 
University Edition, which contains SAS Studio 3.6 and SAS 9.4, was used for all analyses.
RESULTS
Sample characteristics
Participants (N=348) ranged in age from 24 to 88 years old (X− = 51.28, SD = 11.04). The 
majority were female (n=197, 56.61%) and Caucasian (n=293, 84.20%). On average, 
participants smoked over 15 cigarettes per day (X− = 15.81, SD= 8.66). Table 1 presents 
demographic information and PPR status stratified by marijuana use. Chi-square tests and an 
ANOVA revealed no significant differences in sample characteristics across marijuana never, 
ever, and current users. A significant difference was found between marijuana never, ever, 
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and current users for PPR status (χ2 = 14.84, df = 4, p = 0.005). We tested three 
comparisons (never/ever, never/current, ever/current) using SAS proc multest, which 
provides Bonferroni adjusted p values. A significant difference remained for the following 
PPR use groups: never vs. ever (p=0.009) and never vs. current (p=0.022).
Relationship between marijuana and PPR use
As shown in Table 2, logistic regression was used to further examine the relationship 
between marijuana and PPR use, with PPR current use set as the reference category for the 
criterion variable and marijuana never use set as the reference category for the predictor 
variable. The model was adjusted for all sample characteristics, and compared to marijuana 
never users, both marijuana ever users and current users were more likely to have used PPRs 
in the past 30 days, with ever users having an AOR=2.58 (95% CI: 1.51–4.43) and current 
users having an AOR=3.38 (CI: 1.76–6.49). A logistic regression was used to investigate the 
relationship between the frequency of marijuana use among current marijuana users and 
PPR use, and no significant results were found (Table 3).
DISCUSSION
Results suggest that adult current cigarette smokers have differential use of PPRs depending 
on their use of marijuana. Those who were current and ever marijuana users were over 2–3 
times more likely to have used PPRs in the past 30 days, respectively, when compared to 
cigarette smokers who never used marijuana.
Results support the findings of previous studies that addressed a possible complementary 
effect of marijuana use with PPR use. Novak, Peiper, and Zarkin (2016) analyzed NSDUH 
data in 2003 and 2013 and found that greater marijuana use was associated with more 
frequent PPR use. An analysis of NESARC data found higher levels of marijuana and 
cigarette use predicted initiation, re-initiation, and sustained opioid use (Arterberry et al. 
2016); and another study using NESARC data determined that marijuana use was associated 
with an elevated risk of using nonmedical prescription opioids three years later (Olfson et al. 
2018). Two Swedish teams found similar results. One study found a positive association 
between use of marijuana and unauthorized use of PPRs (Berge, Hakansson & Berglund 
2014). In a re-analysis of a Swedish national household survey, non-medical PPR use was 
associated with both frequent cigarette smoking and marijuana use (Abrahamsson & 
Hakansson 2015). Studies with adolescent and young adult samples found non-medical use 
of PPRs is associated with marijuana use (McCabe et al. 2012; Catalano et al. 2011).
Though longitudinal studies are needed to make definitive conclusions about the nature of 
the relationship between marijuana and PPR use among cigarette smokers, the interface 
among biological effects of PPRs, marijuana, and nicotine could influence the strength and 
direction of this relationship. For one, PPRs and marijuana share anti-nociceptive effects, the 
two substances act on some of the same brain regions, and THC partly exerts its analgesic 
influence by relying on opioid receptors (Pacula et al. 2015; Abrams & Guzman 2015; 
Maione et al. 2011; Cichewicz 2004). Nicotine additionally interacts with the opioid system, 
and the systems have almost identical influences in key pleasure-sensing areas of the brain 
(McGehee 2006). Therefore, the behavioral responses to nicotine use and withdrawal 
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(including reward and addiction) are likely affected by the opioid system (Hadjiconstantinou 
& Neff 2011; Berrendero et al. 2010). As with marijuana and opioids, nicotine has anti-
nociceptive actions (Kishioka et al. 2014; Ditre et al. 2016). Consequently, the 
interconnected neural activity and biological effects of nicotine, marijuana, and opioids 
could play a role in the relationship between PPR and marijuana use among cigarette 
smokers.
Another explanation for the higher likelihood of current PPR use among ever and current 
marijuana users in cigarette smokers could be that some participants had used marijuana 
and/or PPRs to reduce pain symptoms. Epidemiologic and prospective cohort studies point 
to a relationship between smoking and chronic pain, with smokers having a greater 
likelihood of developing chronic pain disorders than non-smokers (Shi et al. 2010). And the 
most frequently reported reason for adult misuse of PPRs in 2015 was to alleviate physical 
pain (Lipari, Williams, and Van Horn 2017).
Our results do not support prior findings of a negative association between marijuana and 
PPR use. Boehnke, Litinas, and Clauw (2016) report that among individuals with chronic 
pain, use of medical marijuana was negatively associated with opioid use. Further, 
legalization of medical marijuana has been correlated with a drop in the number of 
hospitalizations attributed to opioid dependence/abuse and PPR ODs, and a decline in opioid 
OD mortality rates (Shi 2017; Bachhuber et al. 2014). States with medical marijuana 
dispensaries also report fewer PPR ODs, a reduction in PPR treatment admissions, and a 
decline in opioid-related deaths (Pardo 2016; Powell 2015). However, none of these studies 
stratified their results by cigarette smoking status. As such, it is possible that the inclusion of 
only current cigarette smokers in the present study could help explain the discrepancy 
between the present findings and other results.
Of note, studies investigating the effect of marijuana use on opioid/PPR use vary in their 
sample composition (i.e., age, health status, drug use status), use of covariates (i.e., 
legalization of medical marijuana or specific components of medical marijuana laws), and 
outcome measures (i.e., use/abuse of PPRs and/or opioids in general, hospitalizations due to 
use of PPRs and/or opioids in general, mortality due to use of PPRs and/or opioids in 
general). This variation in study design is likely responsible for some of the discrepant 
findings in the extant literature. As previous studies have not stratified their analyses by 
cigarette smoking status, our study provides an important and unique contribution to current 
evidence, and this dynamic helps to explain why our findings differ from those that found a 
negative relationship between marijuana and PPR use.
We did not find a significant association between PPR use and frequency of marijuana use 
among current marijuana users. Our findings align with those of Lucas et al. (2013), who 
determined that among Canadian medical marijuana users, there was no association between 
frequency of marijuana use and illicit drug substitution, though this finding is attenuated 
because their analysis was not stratified by cigarette use status. On the other hand, our 
findings contrast with those of Arterberry et al. (2016), who reported that frequency of 
marijuana and cigarette use was predictive of opioid use among an adult sample in the 
NESARC. This dissimilarity may be due to differences in study design. In the work of 
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Arterberry et al. (2016), frequency of marijuana use was determined by asking participants 
how often they used marijuana in the last year, and responses were coded on a scale from 0 
(never used) to 10 (used every day). In contrast, our participants reported how often they 
used marijuana within the past month by indicating a specific number of days from 0–30. 
Second, all participants in our study were current cigarette smokers, while the NESARC 
sample included both cigarette smokers and non-smokers.
There are several study limitations. Though the TABS II used a random sample, it is not 
nationally representative. All data is self-reported, and there are no biomarkers for 
verification of tobacco, marijuana, or PPR use. The cross-sectional nature of the analysis 
prevents causal inference. As there were no non-smokers included in the analysis to compare 
with the current smokers, further analysis of the present study is warranted. We do not have 
data on participants’ reason for PPR use. Some participants could have medical provider-
issued prescriptions for pain, yet it is possible that even patients with valid prescriptions may 
not actually “need” a prescription pain reliever. We did not have any information on the 
presence, absence, or type of pain. Studies have shown that simply asking a primary care 
physician for a narcotic by brand name significantly increases the likelihood of being 
prescribed a medication and being prescribed a strong narcotic (McKinlay 2014). Because 
pain is subjective, a definitive conclusion as to what level pain a patient is experiencing is 
not possible. Therefore, the only data available in a large data base is whether or not the 
participant had a prescription for use. We also did not measure the frequency of PPR use 
within the past 30 days, as we did with marijuana, nor did we ask respondents about the 
type(s) of PPRs they used. In the future, questions about these details of PPR use would be 
beneficial to include, as they would enable a more nuanced analysis of the data. Concerning 
our frequency analysis, it is possible that our sample of current marijuana users (N=76) was 
too small to capture a significant effect between frequency of marijuana use and PPR use. 
Finally, despite random sampling, our sample was predominantly Caucasian and older, 
limiting generalizability.
To frame conclusions about the presence of a complementary effect between marijuana and 
PPR use and to identify a potential causal relationship between use of these two substances, 
future studies should be longitudinal, with larger and more diverse samples that include both 
smokers and non-smokers. The incorporation of unique aspects of MMLs (i.e., home 
cultivation, registration requirements, and dispensaries) into future models would be useful 
to more accurately determine the effects of such laws.
Conclusions
Findings suggests that if adult current cigarette smokers are also current or ever marijuana 
users, they are more likely to be PPR users. These results can inform 1) policy changes for 
those who work in substance use and tobacco control to encourage prevention and increase 
education about the risks of using these substances and 2) practice guidelines for healthcare 
providers, as the combination of being a current cigarette smoker and an ever or current 
marijuana user increases the chances of being a current PPR user when compared to those 
who have never used marijuana. In light of the current national opioid epidemic (Rudd et al. 
2016; SAMHSA 2013; Cai et al. 2010), clinicians should proceed with caution when 
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prescribing PPRs to cigarette smokers and provide patients with information about the risks 
of opioid use. The present results and findings from similar studies thus have important 
public health implications and should be followed up with additional longitudinal studies to 
further elucidate the interplay between marijuana, cigarette, and PPR use.
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Table 1
Sample characteristics and PPR status stratified by marijuana use among current cigarette smokers (N=348).
Marijuana use – n (%), M (SD)
p-valueNever
(n=69)
Ever
(n=203)
Current
(n=76)
Age 0.157
52.65 (11.50) 51.57 (10.80) 49.28 (11.11)
Gender 0.546
  Male 26 (17.22) 90 (59.60) 35 (23.18)
  Female 43 (21.83) 113 (57.36) 41 (20.81)
Race/Ethnicity 0.314
  Caucasian/White 56 (19.11) 176 (60.07) 61 (20.82)
  Other 13 (23.64) 27 (49.09) 15 (27.27)
Education 0.706
  High school or less 23 (21.12) 61 (58.65) 20 (19.23)
  Some college 23 (16.43) 83 (59.29) 34 (24.29)
  College graduate or higher 23 (22.12) 59 (56.73) 22 (21.15)
Occupational status 0.096
  Employed 33 (19.53) 102 (60.36) 34 (20.12)
  Unemployed 6 (12.00) 25 (50.00) 19 (38.00)
  Retired 17 (21.79) 48 (61.54) 13 (16.67)
  Other 13 (25.49) 28 (54.90) 10 (19.61)
Type of community 0.917
  Urban 18 (18.56) 56 (57.73) 23 (23.71)
  Rural 20 (20.62) 59 (60.82) 18 (18.56)
  Suburban 31(20.13) 88 (57.14) 35 (22.73)
Cigarettes smoked per day 0.145
17.54 (9.08) 15.60 (8.91) 14.82 (7.36)
MML status in state of residence 0.217
  Not legal 31 (18.02) 108 (62.79) 33 (19.19)
  Legal <10 years 29 (23.58) 68 (55.28) 26 (21.14)
  Legal ≥ 10 years 9 (16.98) 27 (50.94) 17 (32.08)
PPR status 0.005*
  Never 30 (43.48) 45 (22.17) 15 (19.74)
  Ever 26 (37.68) 105 (51.72) 37 (48.68)
  Current 13 (18.84) 53 (26.11) 24 (31.58)
Notes:
(1) p-values were calculated by using an ANOVA for the continuous variables (age and average cigarettes smoked per day) and chi-square tests for 
the categorical variables (gender, race/ethnicity, education, occupational status, type of community, MML status in state of residence, and PPR 
status)
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*(2) significant at p=0.05 level
Bonferroni adjusted p-values for the chi-square test between PPR status and marijuana use status: marijuana never vs. ever p=0.009, marijuana 
never vs. current p=0.022, marijuana ever vs. current p=1.00
(3) Abbreviations: “PPR” = prescription pain reliever; “MML” = medical marijuana law
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Table 2
Association between marijuana use status and current PPR use (N=348).
Unadjusted Adjusted
OR 95% CI AOR 95% CI
Marijuana use
 Never (ref) 1 - 1 -
 Ever 2.22* 1.32 – 3.74 2.58* 1.51 – 4.43
 Current 2.74* 1.47 – 5.11 3.38* 1.76 – 6.49
Notes:
(1) The adjusted model incorporates sample characteristics (gender, race/ethnicity, education, occupational status, age, average cigarettes smoked 
per day, type of community, and MML status in state of residence)
*(2) significant at p=0.05 level
(3) Abbreviations: “PPR” = prescription pain reliever; “OR” = odds ratio; “CI” = confidence interval; “MML” = medical marijuana law
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Table 3
Logistic regression results for effect of frequency of marijuana use in the past 30 days upon PPR status, among 
current marijuana users (N=76).
PPR Status Logistic Regression
Never
(n=15)
Ever
(n=37)
Current
(n=24)
OR (95% CI) p-value
Days used
marijuana in
past 30 days
11.20
(10.59)
15.41
(12.37)
13.21
(11.87)
1.01
(0.97–1.04) 0.796
Notes:
(1) Abbreviations: “PPR” = prescription pain reliever; “OR” = odds ratio; “CI” = confidence interval
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